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Abstract
Phenalenones are polyketide natural products that display diverse structures and biological 
activities. The core of phenalenones is a peri-fused tricyclic ring system cyclized from a linear 
polyketide precursor via unresolved mechanism. Towards understanding the unusual cyclization 
steps, the phn biosynthetic gene cluster responsible for herqueinone biosynthesis was identified 
from the genome of Penicillium herquei. A nonreducing polyketide synthase (NR-PKS) PhnA was 
shown to synthesize the heptaketide backbone and cyclize it into the angular, hemiketal-containing 
naphtho-γ-pyrone prephenalenone. The product template (PT) domain of PhnA catalyzes only the 
C4–C9 aldol condensation, which is unprecedented among known PT domains. The 
transformation of prephenalenone to phenalenone requires an FAD-dependent monooxygenase 
(FMO) PhnB, which catalyzes C2 aromatic hydroxylation of prephenalenone and ring opening of 
the γ-pyrone ring simultaneously. Density functional theory calculations provide insights into why 
the hydroxylated intermediate undergoes an aldol-like phenoxide-ketone cyclization to yield the 
phenalenone core. This study therefore unveiled new routes and biocatalysts for polyketide 
cyclization.
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INTRODUCTION
Fungal aromatic polyketides constitute a large group of natural products with diverse 
biological activities towards plants, animals and humans, ranging from beneficial such as the 
antifungal griseofulvin to the carcinogenic aflatoxin.1 The polycyclic core of aromatic 
polyketides is formed from a cascade of well-controlled intramolecular cyclization reactions 
starting with a poly-β-keto-thioester backbone, which is synthesized from malonyl-CoA by 
non-reducing polyketide synthases (NR-PKSs).2 NR-PKSs are megasynthases that contain 
linearly juxtaposed catalytic domains that typically include SAT (starter-unit:ACP 
transacylase),3 KS (β-ketosynthase), MAT (malonyl-CoA:ACP transacylase), PT (product 
template),4 ACP (acyl-carrier protein)5 and TE/CLC (thioesterase/Claisen-like Cyclase)6 
(Figure 1). Following formation of the reactive poly-β-ketone chain by the collective 
functions of KS, MAT and ACP domains, the PT domain is responsible for the regioselective 
intramolecular aldol condensation steps that form the first (and sometimes accompanied by 
the second) aromatic rings.4,7 Different cyclization regioselectivities for the first ring 
cyclization (e.g., C2–C7, C4–C9, C6–C11 and C8–C138) by individual PT domains give rise 
to the structural diversity observed among fungal aromatic polyketides. Following the 
actions of the PT domain, the terminal TE/CLC domain can further catalyze Claisen-like 
condensation reactions that form additional rings, and also release the polyketide product 
that is attached as a thioester on the ACP domain of the megasynthase.6,9 Interestingly, all 
NR-PKSs characterized to date produce linearly fused, aromatic compounds, including 
naphtho-xanthone (SMA76a10), anthraquinone (norsolorinic acid7c), naphtho-γ-pyrone 
(YWA1,6 1), etc (Figure 1A). The activities of the corresponding PT and TE/CLC domains 
have been well-studied, establishing sequence-activity relationships that have enabled NR-
PKS product prediction and engineering.7a,7b,11
In contrast to nearly all biosynthetically characterized fungal aromatic polyketides, the 
phenalenone family of compounds contain a “non-linearly” cyclized tricyclic core in which 
a benzene ring is peri-fused to a naphthalene.12 The core is heavily derivatized and oxidized 
to afford structurally diverse natural products and significant biological activities, including 
the antibacterial (+)-deoxyherqueinone 2 and herqueinone 3, and the anticancer duclauxin 4 
(Figure 1B), as well as numerous derivatives shown in Figure S1.13 Penicillium herquei and 
related fungal strains are prolific producers of phenalenones; and compounds from 
fermentation of P. herquei have been reported to treat tumors, bacterial infections and/or 
mycoses and rheumatic diseases.14 Isotope feeding studies have confirmed the phenalenone 
core of 3 is derived from seven acetate units (heptaketide) and therefore should be catalyzed 
by a NR-PKS (Figure 1C).15 Following formation of the cyclized polyketide core, 
phenalenones are presumed to be modified by post-PKS tailoring enzymes including C2 
hydroxylation and O-methylation, prenylation and formation of the fused furan ring, and 
other transformations to generate the final natural products.12,16
The 13C-labeling patterns of 3 from feeding studies suggest the phenalenone core is formed 
through a unique combination of three regioselective cyclization steps,15 including one 
aldol-condensation step that connect either C4–C9 or C8–C13, a Claisen-like condensation 
step that connects C1–C10 and releases the polyketide, and an additional aldol-like C-C 
bond forming step between either C8–C13 or C4–C9, whichever is not formed in the first 
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aldol condensation step (Figure 1C). To date, all C-C bond forming steps during cyclization 
of linearly fused aromatic polyketides are between an enolate and a carbonyl in uncyclized 
portions of the polyketide chain.2 In contrast, to generate the peri-fused ring system in 
phenalenones, regardless of the order of the three cyclization steps, we propose that one of 
the carbon-carbon bond formation steps (C8–C13 or C4–C9) requires generation of a 
phenoxide nucleophile from a previously cyclized aromatic ring (Figure S2). Hence to 
complete this cascade of cyclization reactions on a heptaketide precursor, the PT and 
TE/CLC domains must possess features that are unique compared to those involved in the 
formation of the linearly fused products; and/or other partnering enzymes may be involved 
as well. Elucidating the biochemical basis of the phenalenone cyclization steps can therefore 
increase our understanding of fungal aromatic polyketide biosynthesis and ability towards 
biosynthetic engineering.
In this study, we report the identification of the phn biosynthetic gene cluster from P. herquei 
and biochemical characterization of the NR-PKS PhnA involved in phenalenone 
biosynthesis. We show that PhnA synthesizes a novel angular naphtha-γ-pyrone product, 
which is oxidatively morphed into the phenalenone structure by a flavin-dependent 
monooxygenase (FMO) PhnB. Through density functional theory (DFT) calculations, we 
propose a mechanism for the reaction. The combined activities of PhnA and PhnB represent 
a new strategy of polyketide cyclization in nature.
RESULTS
Identification of the phn biosynthetic gene cluster and the PhnA NR-PKS
We first confirmed the production of phenalenones from P. herquei (NRRL 1040). 
Herqueinone 3 was observed as the major product following two days of cultivation on 
Potato dextrose agar (PDA) for 2 days (Figure 2B). The compound was purified and 
structurally verified to be 3 when compared to literature reports (Figures S7, S24 and 
S25).17 The 33 Mb draft genome of P. herquei was then obtained using Illumina HiSeq 2000 
sequencing, assembled and annotated using SOAPdenovo.18 Bioinformatic analysis using 
antiSMASH19 revealed the organism to encode 10 biosynthetic gene clusters that may 
contain a NR-PKS (Table S2). We identified one putative gene cluster on contig 424 56.6 
that may be responsible for the biosynthesis of 3 (Figure 2A and Table S3). In addition to an 
encoded NR-PKS (PhnA) which has the domain architecture of SAT-KS-MAT-PT-ACP-
ACP-TE/CLC, neighboring genes encode FMO (PhnB and PhnG), O-MT (PhnC) and 
prenyltransferase (PrT, PhnF) that are consistent with the structural features of 3. RT-PCR 
analysis showed that transcription of the phn genes are synchronized with the production of 
3 in P. herquei (Figure S3). To confirm the involvement of phnA in the biosynthesis of 3, we 
performed genetic knockout of the KS region of phnA using homologous recombination and 
hygromycin as selection marker (Figure S4). Deletion of phnA completely abolished the 
production of 3 (Figure 2B), thereby establishing the link between the phn cluster and 
biosynthesis of 3 in P. herquei.
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Functional Characterization of the phn NR-PKS PhnA
To identify the polyketide product of PhnA and the functions of its cyclization domains, the 
intron-less phnA was cloned under ADH2 promoter on a 2µ plasmid and transformed into 
the engineered Saccharomyces cerevisiae strain BJ5464-NpgA.20 After three days of 
culturing, the yeast culture exhibits a darker brown color not observed with the control 
strain. LC-MS analysis of the extracted metabolites showed accumulation of a new 
compound 5 (m/z 277 [M+H]+, Figure 3 and S8) and a minor product 6 (m/z 259 [M+H]+, 
Figure S9). Both 5 and 6 were isolated from yeast (5 mg/L and 0.3 mg/L respectively) and 
the structures were determined by extensive NMR analysis (Table S6, Figures S26–S34). 
Both compounds are heptaketide products with a tetrahydroxylnaphthalene (THN) core 
angularly fused to a γ-pyrone ring. While the pyrone ring in 5 (named prephenalenone) 
contains a hemiketal that is formed upon attack of the C1 hydroxyl group on the C13 ketone, 
6 exists as a mixture of two interconverting tautomers that forms after dehydration of 5 
(Figure 2C and S9). The dehydration occurs spontaneously under aqueous and room 
temperature conditions within 48 hours (Figure S14A), which was similarly observed for the 
conversion of the linear naphthopyrone YWA1 1 into nor-rubrofusarin even in the absence of 
a dedicated dehydratase.21 To test whether 5 is an on-pathway intermediate in the 
biosynthesis of 3, purified 5 was added to the ΔphnA blocked mutant at 50 mg/L. LC-MS 
analysis of the culture after 72 hours showed that production of 3 was restored while minor 
conversion to 6 was observed (Figure 2B). In contrast, chemical complementation of ΔphnA 
using 6 did not restore the production of 3.
To demonstrate PhnA is the enzyme required to synthesize 5, recombinant PhnA (237 kDa) 
was purified from yeast to homogeneity and assayed in the presence of 2 mM malonyl-CoA 
in vitro (Figure S5). The predominant product of the assay was indeed confirmed to be 5 
upon LC-MS analysis, with a small amount of 6 present (Figure 4). Repeating the assay 
using [2-13C]-malonyl-CoA that is generated in situ from [2-13C]-malonate, coenzyme A 
and MatB22 showed an increase in mass of 5 by seven mass units (m/z 282 [M-H]−), 
consistent with the heptaketide backbone of 5 (Figure S15). Hence, PhnA is solely 
responsible for the production of 5, which must be derived from an uncyclized heptaketide 
precursor via the sequential cyclization of C4–C9 aldol condensation and C1–C10 Claisen-
like condensation to generate the THN intermediate 12, followed by attack of C1-OH on 
C-13 to form the naphtho-γ-pyrone (Figure 5). This sequence of cyclization events is 
parallel to that involved in the formation of the linearly fused 1 with key differences in 
regioselectivities of the first aldol-condensation step (C2–C7 instead of C4–C9) (Figure 5).6
Delineating the Roles of PT and TE/CLC of PhnA
While PT-catalyzed C4–C9 cyclization of polyketides was previously observed in the 
formation of norsolorinic acid and nor-toralactone (Figure 5), the first ring cyclization steps 
are always accompanied by the consecutive C2–C11 aldol condensation that is likely also 
catalyzed by the respective PT domains.7c,23 Hence a PT domain that performs only a single 
C4–C9 aldol condensation as required in the formation of 5 has not been previously 
reported. To investigate the role of the PT domain, as well as the TE/CLC domain, we 
constructed two version of PhnA that is inactivated in the TE/CLC domain (PhnA TE0).9a 
Both the active site serine to alanine mutant (S2009A) and the TE deletion (ΔTE) versions of 
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PhnA were expressed in BJ5464-NpgA, followed by metabolite analysis as shown in Figure 
3. LC-MS analysis showed that both mutants lost the ability to produce 5 and 6, but instead 
accumulated two new compounds 7 and 8 with the same mass (m/z 279 [M+H]+). Both 
compounds were isolated from yeast culture (2 mg/L for 7, Figure S10; 0.4 mg/L for 8, 
Figure S11) and their structures were elucidated by NMR analysis (Table S7 and Figures 
S35–S44). Both new compounds are featured by a bicyclic system in which the 1,3-
dihydroxybenzene ring is fused to either an eight-membered (7) or a ten-membered 
macrolactone (8). Compared to 5, it is evident that while the TE/CLC mutation abolished the 
second aromatic ring in 5 that is derived from the C1–C10 Claisen-condensation, the first 
aromatic ring that is fixed from C4–C9 aldol condensation remained intact. This confirms 
the PT domain in PhnA is only responsible for directing the C4–C9 cyclization, while the 
TE/CLC domain catalyzes the C1–C10 cyclization. Formation of the macrolactones 7 and 8 
requires ketoreduction of the C11 and C13 carbonyl groups, respectively, and the subsequent 
attack by the hydroxyl groups on the C1 thioester (Figure 5). We propose that the 
ketoreduction steps are catalyzed by endogenous yeast ketoreductases as observed 
previously with other ketone-containing compounds.24 Mutation in the PhnA TE/CLC 
domain inactivates the release of 12 and stalls the resorcinol-containing thioester 
intermediate on the ACP domain. This stalling likely enables access of the ketone groups by 
yeast KR enzymes and leads to macrolactone formation. To verify that the reduction 
activities do not reside in PhnA, both TE0 mutants were purified from yeast and assayed in 
the presence of malonyl-CoA. As expected, no product turnover was observed from the in 
vitro reactions.
FMO-Catalyzed Formation of Phenalenone
Previous work with WA that produces 1 led to proposal that formation of the hemiketal may 
also be promoted by the TE/CLC domain.6 We explored the energetics of various species 
involved in their transformation by DFT computations (see Supporting Information for 
details). These computations show that the hemiketal 5 is ~ 3.7 kcal/mol more stable than 
the ring-opened diketo-THN 12 (Figure S19). This explains why 12 is not observed during 
isolation and characterization of 5. Indeed, the hemiketal γ-pyrone is very stable even under 
strongly acidic treatment (10% trifluoroacetic acid in DMSO) (Figure S16). Therefore based 
on the chemical complementation result that 5 is a biosynthetic precursor of 3, additional 
enzyme(s) must be required to open the γ-pyrone ring to facilitate the formation of the last 
ring (C8–C13 bond formation) to yield a phenalenone product, such as 13 (Figure 6).
To identify the enzyme(s) responsible for pyrone opening and C8–C13 cyclization, we 
targeted the deletion of selected phn genes and search for the mutant that accumulates 5. 
PhnC encodes a small protein (15 kDa) that belongs to the dimeric α/β barrel (Dabb) protein 
superfamily including the plant polyketide olivetolic acid cyclase (OAC) that catalyzes a 
C2–C7 intramolecular aldol condensation.25 However, deletion of this gene led to only 
decreased, but not abolished production of 3. Meanwhile, structural comparison of all the 
reported phenalenone-containing fungal natural products showed that the C2 position is 
invariably oxidized to either a C2-OH (or methoxy) or a C2-keto functional group (Figure 
1B).12 This common feature perhaps hinted that the hydroxylation of C2 may somehow be 
required for the formation of the phenalenone core. To test this hypothesis, we inactivated 
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phnB which encodes a FAD-dependent hydroxylase that has sequence homology to UbiH, 
the 2-octaprenyl-6-methoxyphenol aromatic hydroxylase in ubiquinone biosynthesis.26 
Interestingly, the ΔphnB mutant lost the ability to produce 3 and accumulated 5 as the 
predominant product (Figure 2B), hinting that PhnB is the immediate downstream enzyme 
of PhnA and must play an important role in transforming 5 into a phenalenone structure.
Recombinant PhnB (45 kDa) was expressed and purified from Escherichia coli BL21(DE3) 
as a yellow-hued protein. Addition of PhnB and NADPH to the in vitro assay containing 
PhnA led to the formation of two new compounds, 9 (m/z 275 [M+H]+) and 10 (m/z 273 [M
+H]+), as well as residual amount of 6 (Figure 4). When 5 µM PhnB was directly added to 1 
mM 5 in the absence of PhnA, we observed the rapid conversion of 5 to 9 (complete 
consumption of 5 in ~80 minutes), accompanied by the gradual and eventual complete 
conversion of 9 to 10. To determine the structure of 9 and 10, we coexpressed PhnA and 
PhnB in BJ5464-NpgA, which led to the accumulation of both 5 and 9 after three days of 
culturing. Work up of the culture showed most of 9 was found intracellularly and remained 
intact, which enabled purification and structural elucidation (Figure 3). No trace of 13 (m/z 
259 [M+H]+) can be found in the product mixture isolated from the in vitro and in vivo 
assays involving PhnB, consistent with previous observations that all isolated phenalenones 
are oxidized at C2.
Purification of 9 proved to be challenging as it is unstable and prone to conversion into 10 
and other products during isolation under room temperature conditions (Figure S14B). We 
optimized the conditions and used a low-temperature isolation and purification procedure 
(See Methods for details) to obtain relative pure 9 for NMR characterization. Key HMBC 
correlations between 14-CH3 to C12, C13 and C8; and from H6 to C4, C5, C7 and C8; and 
from H12 to C8 and C10, C13, and C14 unequivocally established the structure of 9 to 
contain the intact fused phenalenone core (Table S8 and Figures S45–S48). However, due to 
tautomerization between C1, C2 and C3 and lack of additional proton signals, the structure 
of the northern portion of the molecule could not be fixed, which is also observed for the 
phenalenone product atrovenetin.27 However, combining the MS and NMR data, we believe 
one form of 9 is indeed the C2-oxidized phenalenone structure as shown in Figure 3. To 
determine if 9 is a true intermediate in the biosynthesis of 3, purified 9 was added to the 
ΔphnA strain. Despite its instability under culturing conditions, we observed restoration of 3 
in the chemical complementation experiment with approximately 5% conversion of 9 
(Figure 2B). The conversion of 9 to 10 is spontaneous in air which suggests 10 may be the 
oxidized, tri-keto product (Figure 4 and Figure S14B). 10 was very unstable and also rapidly 
degraded during purification. However, 10 could be converted to a stable aldol adduct 11 
(m/z 331 [M+H]+) when treated with acetone (Figure S14C), which is a common feature of 
phenalenones.12 11 can be purified and its structure was established by NMR analysis (Table 
S8 and Figures S49–S52). The acetone adduct at C2 was unambiguously determined, which 
supports the structure of 10, as well as that of the phenalenone core in 9.
To probe the substrate requirement of PhnB, we first used the dehydrated product 6 as a 
substrate analogue. No reaction was observed indicating the hemiketal and the C13-OH are 
essential for the C2 hydroxylation activities. This suggests the C2 hydroxylation is not via 
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the canonical monooxygenase mechanism that involves deprotonation of ortho- or para- 
substituted phenolic oxygen (such as C4-OH in 5).28 We then aimed to generate an 
uncyclized THN substrate that does not contain a C13 ketone group. To do so, we performed 
the PhnA in vitro assay using butyryl-SNAC as a starter unit. When presented with the four-
carbon primer unit, PhnA synthesized a new product 18 (m/z 263 [M+H]+) that is derived 
from a butyryl-primed C18 product (Figure S17). Although this compound was not isolated 
for structural characterization from the in vitro reaction, based on the mass, number of 
ketide units from [2-13C]-malonate assay, and the identical UV absorbance to other THN 
compounds (Figure S18), we can propose the structure is the butanone-substituted THN as 
shown in Figure 6. To probe if PhnB can oxidize the C2 position of 18, we performed the in 
vitro assay in the presence of both PhnA and PhnB. No transformation of 18 can be detected 
(Figure S18), further supporting PhnB requires the pyrone ring of 5 for catalysis.
Proposed Mechanism of Phenalenone Formation
Our studies show that PhnB is responsible for converting γ-pyrone 5 into the tricyclic 
phenalenone as well as C2 hydroxylation. These two reactions appear to take place together, 
since attempts to isolate either C2 hydroxylated γ-pyrone 17 or unhydroxylated phenalenone 
13 were unsuccessful. Taking this into consideration, we propose the mechanism of PhnB as 
shown in Figure 6. Following release of the polyketide product from PhnA and rapid 
formation of the hemiketal 5, the active site of PhnB initiates the reaction through base-
catalyzed deprotonation of C13-OH, which leads to cleavage of the pyrone ring and enables 
the nucleophilic attack of C2 on the oxidized PhnB Fl-4a-OOH to yield intermediate ketone 
14. Subsequently, deprotonation of the C3-OH group leads to nucleophilic attack of the 
electron-rich naphthalene ring at C8 on the now accessible C13 ketone to yield the cyclized 
16 via the transition state 15, by intramolecular proton transfer from the C7-OH, shown to 
be facile by computational studies discussed below. This reaction is very fast when the C2-
OH is present, which increases the acidity of the C3-OH. Intermediate 16 will aromatize 
through dehydration and keto-enol tautomerization to yield the phenalenone product 9.
The purpose and timing of the C2 oxidation are particularly intriguing. Strategically, one can 
reason nature incorporated this step to i) oxidatively cleave the γ-pyrone ring to make the 
C13 ketone available for C8–C13 bond formation; ii) possibly electronically favor the C8–
C13 reaction with 14 to yield 16; or iii) serve as the site for downstream tailoring 
modifications that are important for phenalenone biological activities. It is likely that a 
combination of all three objectives is achieved in this PhnB-catalyzed reaction. With regard 
to the second point, the phenalenone cyclization reaction with 14 must occur very rapidly 
once the C13 carbonyl is exposed, as the competing formation of hemiketal 17 is not 
observed despite being 2.7 kcal/mol more stable (Figures 6, S19 and S20). To understand 
this concerted aldol-like process that forms the third aromatic ring starting from the 
hemiketal, we performed DFT calculations on the energetics of the cyclization (See Methods 
for details). In the absence of deprotonation, the aromatic cyclization reaction would be slow 
at room temperature (ΔG‡298 = 24.4 kcal/mol starting from 5 via 12 with a computed t1/2 
(25°C) =24 h, Figures S19 and S20), but the hydroxylation makes the aromatic cyclization 
~50 times faster (ΔG‡298 = 22.1 kcal/mol starting from 17 via 14, Figures S19 and S20). The 
C5-OH of 14 is a more powerful donor when hydrogen-bonded to C3-O and stabilizes the 
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enone transition state 15 and product of the intramolecular aldol-like process (Figures S21 
and S22). The calculated slow rate of cyclization prompted us to examine the effect of 
deprotonation of C3-OH. Starting with either 12 or 14, calculations show that deprotonation 
significantly decreases the reaction energy barrier and increases the reaction rate of 
phenalenone rearrangements (t1/2 (25°C)=0.018 s for 12, 0.025 s for 14) (Figures S21 and 
S22). In summary, the active site of PhnB provides the general base to perform 
deprotonation of the more remote hemiketal hydroxyl group in 5 and to cause ring-opening 
of the pyrone with installation of the C2-OH group in 14. Subsequent intramolecular 
deprotonation of C3 phenolic oxygen accelerates phenalenone ring closure to yield 9.
DISCUSSION
In this report, we showed the core of phenalenone polyketides is synthesized by the 
combined functions of a NR-PKS (PhnA) and a FMO (PhnB) that catalyzes an unusual 
aromatic hydroxylation of the NR-PKS product 5. Figure 5 is a summary of PT domain 
regioselectivity in cyclization of heptaketides in fungi. The domain organization of PhnA is 
identical to that of WA that synthesizes YWA1 1, including the uncommon tandem ACP 
domains.6 The two NR-PKSs also share 44% sequence identity and 60% sequence similarity 
across the entire protein sequence. Both NR-PKSs produce a heptaketide product and 
catalyze a parallel set of cyclization reactions, including an intramolecular aldol 
condensation and a C1–C10 Claisen cyclization, to generate the respective naphthopyrone 
products (Figure 5). The only difference between the two NR-PKSs appears to be in the 
regioselectivity of the PT domain: whereas the C2–C7 cyclization controlled by WA leads to 
the linear 1, the C4–C9 cyclization catalyzed by PhnA results in the angular 5. The recently 
characterized CTB1 NR-PKS involved in cercosporin biosynthesis employs a PT domain 
that catalyzes the tandem C4–C9 and C2–C11 aldol cyclizations in the synthesis of nor-
toralactone,23 functions that are similar to the PT domain of PksA that synthesizes 
norsolorinic acid.7c Our work with PhnA, especially with the isolation of shunt products 7 
and 8 from the PhnA TE0 constructs, unequivocally verifies that the C2–C11 aldol 
condensation in polyketide cyclization must be catalyzed by the PT domains such as those in 
CTB1 or PksA as previously proposed. Hence the PhnA PT domain is functionally distinct 
from these C4–C9/C2–C11 PT domains, and is unique in that it catalyzes only the C4–C9 
cyclization. While the NR-PKS for pannorin has not been discovered to date, the PT domain 
responsible must catalyzes consecutive C6–C11 and C4–C13 cyclization reactions to set-up 
angular pyrone formation and product turnover, as illustrated in a mix and match experiment 
involving heterologous domain combinations.11c
Having identified PhnA PT as a new addition to the PT domain diversity, we sought to 
compare its sequence to other PT domains using phylogenetic analysis. We previously 
classified the NR-PKS PT domains into five major groups with each group corresponding to 
a unique first-ring cyclization and/or product size: Group I, C2–C7 and monocyclic; Group 
II, C2–C7 and bicyclic; Group III, C2–C7 and multicyclic; Group IV, C4–C9/C2–C11; and 
Group V, C6–C11/C4–C13.7a We conducted a Basic Local Alignment Search Tool (BLAST) 
search for protein sequences with high similarity to that of PhnA PT domain among 
sequenced fungal genomes. Numerous homologs that share high amino acid identity (50–
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70%) with PhnA PT domain were found, all of which are embedded in NR-PKSs of 
unknown functions and products (Figure S6). Interestingly, several of these homologs were 
included in the previous phylogenetic analysis and were grouped in Group III with other 
C2–C7 specific PT domains, including that of WA. Repeating the PT phylogenetic analysis 
after including PhnA PT and other newly sequenced homologs since then led to a clearer 
classification of them into a separate clade that remains closely related to Group III (Figure 
7 and S6). This finding is surprising and indicates that purely sequence-based phylogenetic 
analysis may mask the true cyclization regioselectivity of PT domains. This also indicates 
that the new group (termed Group VI in Figure 7) that includes PhnA is much more closely 
related to Group III than to Group IV PT domains, despite sharing the same C4–C9 first-ring 
cyclization regioselectivity. Indeed, alignment of PhnA PT domain with PT domains from 
Group III showed high sequence similarity, including numerous strictly conserved residues 
(Figure S23). PhnA PT domain shares 47% sequence identity and 63% sequence similarity 
with WA PT, but only30% sequence identity and 49% sequence similarity to CTB1 PT. We 
can therefore propose that such C4–C9 only PT domains evolved from the Group III NR-
PKSs via a regioselectivity switch, perhaps controlled by a few residues, instead of from 
Group IV PT domains that requires the loss of C2–C11 cyclization capability. The PhnA and 
WA PT domains can therefore serve as intriguing targets for comparative structural studies 
towards unmasking residues that are important for regioselectivity control in highly similar 
domains.
The remaining enzymes encoded in the gene clusters are expected to transform 5 into 3, as 
confirmed through the chemical complementation study. These include PhnC (O-MT) that 
can methylate C2-OH to stabilize the northern portion of the phenalenone core; PhnF (PrT) 
that installs the dimethylallyl group at C5 and PhnG (FMO) that can further hydroxylate C6. 
The precise reaction catalyzed by PhnF, whether it is C7-O prenylation or C6 Friedel-Craft 
alkylation, is not known and will require additional in vitro biochemical verification. 
Formation of the fused tetrahydrofuran moiety may require an additional enzyme, and may 
involve those of unassigned function in or immediately adjacent to the gene cluster. Gene 
clusters containing NR-PKSs identified using PhnA PT domain as the lead were analyzed 
and compared to the phn cluster (Table S4). Each gene cluster contains a close homolog of 
PhnB in close proximity to the NR-PKS, suggesting these clusters most likely also 
synthesize products featuring the phenalenone core (Table S4). Among the strains that 
contain the identified clusters, the ones that have been reported to produce a phenalenone-
containing natural product include funalenone producer Aspergillus niger FO-590429 and 
duclauxin 4 producer Talaromyces stipitatus ATCC 10500.30 Funalenone (Figure S1) is the 
C2-methoxy derivative of 9, and the structural features are reflected in the A. niger gene 
cluster which only contains homologs to PhnA, PhnB, PhnC (O-MT) and PhnD (Table S4). 
Similarly, as expected with the structural features of 4, no homologs of PhnC (O-MT), PhnF 
(PrT) and PhnG (FMO) are found in the T. stipitatus gene cluster that contains the PhnA/
PhnB pair; while additional enzymes required for the oxidative coupling of two phenalenone 
cores are present. Therefore, the various combinations of downstream enzymes found in the 
clusters can serve to predict phenalenone product structures. For example, the clusters from 
Cladophialophora psammophila CBS 110553 and Cladophialophora bantiana CBS 173.52 
contain all the genes found in phn cluster, inferring the potential to produce compounds that 
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are the same as or closely resembling 3. Interestingly, the well-studied Aspergillus terreus 
also encodes a phn-like gene cluster although no report of phenalenone isolation has been 
documented from this strain. Based on the gene cluster which lacks PhnF (PrT), one can 
speculate that this cluster, once transcribed, can produce an unprenylated but C6-
hydroxylated derivative of 3.
In contrast to fungal NR-PKSs, cyclization regioselectivity of the bacterial aromatic 
polyketides is entirely controlled by dissociated tailoring enzymes known as cyclases.2 
Cyclases responsible for linear and angular cyclization of the polyketide chain have been 
well-characterized.2 Resistomycin produced by Streptomyces resistomycificus contains a 
pentacyclic “discoid” ring system, and is therefore structurally similar to the peri-fused 
fungal phenalenones. Reconstitution experiments by Hertweck and coworkers demonstrated 
that formation of the unique discoid fold requires a multi-enzyme complex consists of the 
KSα-KSβ pair (RemA-RemB) and three polyketide cyclases (RemF, L and I).31 It was 
proposed that the five enzymes form a cage-like environment to promote the S-shaped 
folding and aldol cyclization of the backbone. Absence of any of the cyclases leads to 
formation of linear polyketides and other shunt products. The entire ring system in 
resistomycin may therefore be formed through a series of perhaps concerted, aldol 
condensation steps between intact enolates and carbonyls within the multi-enzyme complex. 
This is in sharp contrast to the fungal strategy to generate the phenalenone fold demonstrated 
here. The involvement of the FMO PhnB was initially unanticipated. However, isolation of 
the readily formed and stable hemiketal 5 hinted that modification to the THN ring system to 
promote the C8–C13 reaction must be necessary. The role of PhnB in simultaneously 
cleaving the pyrone ring and activating the C-3 phenolic oxygen via C-2 hydroxylation, as 
confirmed through our theoretical calculations, provides another example of the clever use 
of oxidative enzymes to introduce structural complexity starting from simpler precursors in 
fungal biosynthetic pathways. Both PhnA PT domain and PhnB add to the biocatalytic 
toolbox one can access to rationally control polyketide cyclization towards engineered 
biosynthesis of new aromatic polyketides.
EXPERIMENTAL SECTION
Strains and culture conditions
The Penicillium herquei strain was obtained from Agriculture Research Service (NRRL 
1040) Culture Collection and was used as the parental strain in our study. Both the wild-type 
and the mutant strains were grown on potato dextrose agar (PDA) (20 g/L dextrose, 4 g/L 
potato extract, agar 15 g/L) at 28°C. For gene knock-out in P. herquei, PDA with 1.2 M 
sorbitol and 100 µg/mL hygromycin was used for protoplast regeneration and antibiotic 
resistance selection. Saccharomyces cerevisiae strain BJ5464-NpgA (MATα ura3-52 his3-
Δ200 leu2-Δ1 trp1pep4::HIS3 prb1Δ1.6R can1 GAL) was used. YPD (20 g/L peptone, 10 
g/L yeast extract, 20 g/L dextrose) was used for the routine growth of yeast strain BJ5464-
NpgA and its derivatives at 30°C. SD-drop out media were used for selection of plasmids 
transformed into S. cerevisiae. For protein expression under ADH2 promoter (ADH2p) and 
pathway reconstitution in S. cerevisiae, the appropriate plasmids were introduced into yeast 
cells as described in Table S5. The yeast transformants were initially grown in the 
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appropriate SD-drop out liquid media and then transferred to the liquid YPD media for 
further culture for 4 days. LB media were used for culturing Escherichia coli. E.coli strain 
DH10b was the host for routine plasmid sub-cloning and E. coli strain BL21(DE3) was used 
for protein expression and purification for in vitro assay.
P.herquei RNA preparation and reverse transcription-PCR (RT-PCR)
Mycelia of P. herquei were inoculated in PDB medium at 28°C, 200 RPM for 2 days, and 
collected for lyophilization. The mycelia was grounded after freezing with liquid nitrogen, 
and solubilized in Trizol (Invitrogen). One fifth volume of chloroform was added, vortex and 
centrifuged at 15,000 RPM for 15 min. The supernatant was extracted once again with 
chloroform. RNA was precipitated from the supernatant with ethanol and resuspended in 
RNase-free water. Genomic DNA was further removed by digestion with RNase-free DNase 
I (Ambion). RNA was purified by acid phenol (Ambion) extraction and ethanol 
precipitation. RNA integrity was confirmed by electrophoresis on the TBE (Tris-boric acid-
EDTA) agarose gel, and the concentration was determined by Nanodrop (Thermo 
Scientific). cDNA was prepared from 500 ng of total RNA by SuperScript® II Reverse 
Transcriptase (Invitrogen) with random primers as described by the manufacturer. PCR was 
performed with Phusion® High-Fidelity DNA Polymerase (New England Biolabs) in the 
presence of 25 ng of reverse transcribed RNA. Primers were listed in Table S1.
Plasmid construction
Primers and plasmids were listed in Table S1 and S5, respectively. Yeast expression 
plasmids pXW02 (LEU2 marker), pXW06 (TRP1 marker) and pXW55 (URA3 marker) 
were used for construction of the heterologous expression plasmids by in vivo homologous 
recombination in yeast. All the enzymes were expressed under a strong promoter ADH2p. 
For polyketide synthase PhnA expression, primers S49 + S50, S51 +S52, S53 + S54, 
S55+S56 were used to amplify four DNA fragments of phnA cDNA, and transformed into 
BJ5464-NpgA with SpeI/PmlI-digested pXW55 to create the plasmid pGSS1. For 
polyketide synthase PhnA S2009A expression, primers S49 + S50, S51 +S52, S53 + S54, 
S55+S20b, S21b+S56 were used to amplify five DNA fragments from phnA cDNA, by 
mutating the putative active site (GWSAG) serine (S2009A) in PhnA, and transformed into 
BJ5464-NpgA with SpeI/PmlI-digested pXW55 to create the plasmid pGSS2. For TE-less-
PhnA expression, primers S49 + S50, S51 +S52, S53 + S54, S55+S22b were used to 
amplify four DNA fragments from phnA cDNA, by deletion of 700 bp TE/CLC domain in 
PhnA, and transformed into BJ5464-NpgA with SpeI/PmlI-digested pXW55 to create the 
plasmid pGSS3.Yeast competent cell preparation and transformation were performed with 
S.c. Easy Comp Transformation kit (Invitrogen) according to the manufacture’s protocols. 
Yeast plasmids were prepared by Zymoprep™ Yeast Plasmid Miniprep kit (Zymo Research) 
and transformed into E. coli strain DH10b for propagation. To construct the plasmids for 
gene knock-out in P. herquei based on the split-marker strategy, the plasmid pAN7–14 was 
used as the template to amplify hph upstream fragment with primers hph-up F and hph-up R, 
and hph downstream fragment with primers hph-dn F and hph-dn R. Both fragments were 
digested with NotI/SacII and SacI/NotI, respectively, and ligated to T-vector pTA2 to 
generate plasmids pXM11 and pXM12. The upstream DNA fragments of KS region of phnA 
and phnB were amplified with primer pairs S45 + S46 and S77 + S78. The PCR products 
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were digested with HindIII/NotI (for KO of KS region of phnA) or ClaI/NotI (for KO of 
phnB gene) and ligated to the HindIII/NotI (for KO KS region of phnA) or ClaI/NotI (For 
KO of phnB gene) site of pXM11 to afford plasmids pGSS6, pGSS8, respectively. 
Meanwhile, the downstream DNA fragments of KS region of phnA and phnB were 
amplified with primer pairs S47 + S48, S79 + S80 digested with HindIII/NotI (for KO of KS 
region of phnA) or ClaI/NotI (For KO of phnB gene) and ligated to the HindIII/NotI (for KO 
of KS region of phnA) or ClaI/NotI (For KO of phnB gene) site of to create plasmids pGSS7 
and pGSS9, respectively.
Construction of P. herquei mutants
All the mutants were constructed in P. herquei based on the hygromycin split-marker 
strategy.32 The upstream split-marker DNA for KO of the KS region of phnA and phnB were 
amplified with S45 + S2 and S77 + S2 from plasmids pGSS6 and pGSS8, respectively. The 
downstream split-marker DNA for KO of the KS region of phnA and phnB were amplified 
with S48 + S3 and S80 + S3 from plasmids pGSS7 and pGSS9, respectively. The PCR 
products were gel purified and dissolved in STC buffer. Split-marker DNA was introduced 
into P. herquei by protoplast transformation. P. herquei spores were collected on PDA 
(Fluka) for 4 days at 28°C, and induced to young germ tubes in PDB (Fluka) at 25°C for 7 
hours with 200 RPM agitation. Mycelia were collected, washed twice with the osmotic 
medium (1.2 M MgCl2, 10 mM sodium phosphate, pH 5.8) and resuspended in the enzyme 
cocktail solution (3 mg/mL lysing enzymes, 3 mg/mL yatalase in osmotic medium) at 30°C 
for overnight. After twice wash with STC buffer, protoplasts were gently mixed with DNA 
and incubated for 1 hour on ice. 1 mL of PEG 4000 solution (60% PEG 4000, 50 mM 
CaC12, 50 mM Tris-HCI, pH 7.5) was added to 100 µL of protoplast mixture, incubated at 
room temperature for 30 min and plated on the regeneration selection medium (PDA, 1.2 M 
sorbitol, 100µg/mL hygromycin B). After incubation at room temperature for about 4 days, 
the transformants were inoculated on PDB medium with stationary incubation for about 1 
week to confirm the genotype by PCR after preparation of the genomic DNA.
Yeast reconstitution of phenalenone biosynthesis pathway
S. cerevisiae strain BJ5464-NpgA was transformed with appropriate plasmid(s) as described 
in Table S5. Yeast cells containing transformed plasmid(s) were initially cultured in the drop 
out medium overnight and transferred to 50 mL of liquid YPD medium for additional 4-day 
culture. Extracted samples from approximately 0.5 mL of culture were loaded for LC/MS 
analysis.
Chemical complementation studies
For chemical complementation of ΔphnA strain of P. herquei with compounds (solubilized 
in DMSO), spores of ΔphnA were inoculated in PDA plate together with 10 µg/mL 
compounds 5 and 9, and further cultured for 3 days at 28°C. The mycelia and medium were 
extracted for LC/MS analysis.
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LC/MS analysis
Cultures of P. herquei, S. cerevisiae or E. coli cells were extracted with methanol:ethyl 
acetate (10 : 90). After brief centrifugation, the supernatant organic phase was dried and 
solubilized in methanol for LC/MS injection. All LC-MS analyses were performed on a 
Shimadzu 2020 EVLC-MS (Phenomenex® Luna, 5µ, 2.0 × 100 mm, C18 column) using 
positive and negative mode electrospray ionization with a linear gradient of 5–95% 
acetonitrile (MeCN)-H2O in 15 minutes followed by 95% MeCN for 5 minutes with a flow 
rate of 0.3 mL/min.
Protein expression and purification of PhnB from E. coli strain BL21 (DE3)
The expression plasmid pGSS30 was transformed into E. coli strain BL21 (DE3) for 
expression of PhnB. Cells in LB medium (1 L) supplemented with kanamycin (35 mg/L) 
inoculated with BL21(DE3)/pGSS30 were grown to an OD600 of 0.6. Protein expression 
was then induced with 0.12 mM of isopropylthio-D-galactoside (IPTG, Sigma-Aldrich), 
followed by further incubation with shaking at 250 RPM at 16°C for 16 h. All of the enzyme 
purification steps were conducted at 4°C using Nickel-NTA affinity chromatography 
following standard protocols. Purified proteins were concentrated and exchanged into buffer 
C (50 mM Tris-HCl, pH 7.9, 50 mM NaCl, and 5% glycerol) with Centriprep filters 
(Amicon). The protein was stored in buffer C at −80°C. Protein concentration was 
determined by Bradford assay using bovine serum albumin as a standard.
Protein expression and purification of PhnA from S. cerevisiae strain BJ5464-NpgA
The expression plasmid pGSS1was transformed into S. cerevisiae strain BJ5464-NpgA for 
expression of PhnA. Cells in YPD medium inoculated with BJ5464-NpgA/pGSS1 were 
grown for 3 days for protein expression. S. cerevisiae cells were harvested by centrifugation 
(5000 RPM, 15 min, 4°C), re-suspended in 300 mL yeast lysis buffer and lysed with 
sonication on ice. Cellular debris was removed by centrifugation (17,000g, 1 h, 4°C). FLAG-
tagged proteins were purified by using Anti-FLAGM1 Agarose Affinity Gel (Sigma-
Aldrich), following the supplied protocols. Purified proteins were concentrated, buffer 
exchanged into 50 mM potassium phosphate buffer (pH 7.0) with 10% glycerol, 
concentrated, aliquoted and flash frozen. Protein concentrations were determined using the 
Bradford dye-binding assay (Bio-Rad).
In vitro activity assay for PhnB and PhnA
PhnB activity was assayed by monitoring the conversion of substrates into products as 
analyzed by LC/MS. A typical 100 µL assay solution contained 100 mM potassium 
phosphate buffer (pH 7.5), 4 mM NADPH (Sigma-Aldrich), 20 µM FAD (Sigma-Aldrich), 5 
µM PhnB and 1 mM 5. The reactions was performed at 25°C and quenched with ethyl 
acetate. For in vitro activity assay of PhnA, a typical 100 µL assay solution contained 100 
mM phosphate buffer and 2 mM malonyl coenzyme A lithium salt. The reaction was 
performed at 28°C and quenched with equal volume of methanol. Protein precipitate from 
the reactions was removed by centrifugation. The supernatant was further extracted with 500 
µL ethyl acetate, dried and re-dissolved in 30 µLDMSO and then analyzed on LC-MS. LC-
MS analyses were performed on a Shimadzu 2020 EV LC-MS (Kinetex™ 1.7 µm C18 100 
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Å, LC Column 100 × 2.1 mm) using positive and negative mode electrospray ionization with 
a linear gradient of 5–95% MeCN-H2O in 15 minutes followed by 95% MeCN for 3 minutes 
with a flow rate of 0.3 mL/min.
Chemical analysis and compound isolation
From yeast, the ethyl acetate extract from a 4 L YPD liquid medium was evaporated to 
dryness to yield the crude extract. From P. herquei, the acetone extract from a 2 L PDA solid 
agar extract of mutant was evaporated to dryness and partitioned between ethyl acetate/H2O 
three times. To purify the desired compound, crude extracts were separated by Sephadex-
LH20, reverse phase-C18 and additional HPLC steps as required. Generally, the crude 
extract obtained from the yeast culture or P. herquei cultivated on the PDA solid agar plates 
was submitted to Sephadex-LH20 eluted with methanol. After analysis by the LC-MS, the 
fractions containing the target compound were combined and then submitted to separation 
by ISCO-CombiFlash® Rf 200 (Teledyne Isco, Inc) with a reverse phase-C18 column eluted 
by a gradient of methanol and water. After analysis by LC-MS, the fractions containing the 
target compound was combined and further purified by semi-preparative HPLC using C18 
reverse-phase column. The purity of each compound was checked by LC-MS, and the 
structure was confirmed by NMR. 1H, 13C and 2D NMR spectra were obtained using 
DMSO-d6 or CD3OD as solvent on Bruker AV500 spectrometer with a 5 mm dual cryoprobe 
at the UCLA Molecular Instrumentation Center.
Purification of 9
The crude extract containing 9 was obtained from a 4 day culture of S. cerevisiae BJ5464-
NpgA expressing PhnA and PhnB in YPD broth. The crude extract was subjected to HPLC 
chromatography on a Phenomenex Luna column (250 × 10 mm, 5µm, 40°C, flow 4 mL/min) 
eluted with isocratic wash of 30 % MeCN in water for 20 minutes to yield a sub-fraction. 
The sub-fraction was further subjected to HPLC chromatography on Phenomenex Luna 
column (250 × 10 mm, 5µm, 40°C, flow 4 mL/min) with isocratic wash of 50% MeOH in 
water for 20 minute. The purified fraction was cooled immediately on ice. The solvent was 
quickly removed under reduced pressure, and remaining water was frozen and lyophilized to 
yield 1.5 mg of 9.
Computational methods
Quantum mechanical calculations were performed using Gaussian 09 (Revision D.01).33 All 
geometries were optimized using B3LYP34 and the 6–31G(d) basis set. Single point energies 
were calculated using M06-2X35 and the def2-TZVPP basis set on the B3LYP optimized 
structured. All the results have been calculated in the gas phase at 298K. Computed 
structures were illustrated with CYLView (Legault, C.Y.; CYLview, 1.0b, Université de 
Sherbrooke, 2009 (http://www.cylview.org)).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Aromatic polyketides from fungi. (A) Linear aromatic polyketides synthesized by fungal 
NR-PKS, in which PT and TE/CLC domains control the aromatic cyclization 
regioselectivity; (B) Phenalenones isolated from various fungal species including P. herquei. 
See Figure S1 for more examples; (C) Proposed cyclization steps required to form the 
phenalenone core. See Figure S2 for more details regarding possible order of cyclization 
events. Each thick bond indicates an intact acetate unit.
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Figure 2. 
The phn gene cluster from P. herquei. (A) Organization and proposed function the phn gene 
cluster; TF: transcriptional factor; (B) LC-MS analysis of organic extracts obtained from the 
wild type, different single-gene knockout mutants and chemical complementation studies; 
(C) Structures of the naphtho-γ-pyrone product 5 from the NR-PKS PhnA and the 
dehydration product 6. Each thick bond in 5 indicates an intact acetate unit.
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Figure 3. 
LC-MS analysis of metabolites produced from yeast culture expressing different phn 
enzymes. PhnA alone produced the naphtho-γ-pyrone 5, while addition of PhnB produced 
phenalenone 9. When the TE domain of PhnA was inactivated either by point mutation or 
domain deletion, the shunt products 7 and 8 were observed in yeast. The reduction of either 
C11 or C13 ketone to the hydroxyl groups are likely performed by endogenous yeast 
ketoreductases, as purified PhnA mutants did not produce the same compounds in vitro. The 
peak at ~ 3.5 min is 2-methylbenzoic acid, which is a yeast metabolite.
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Figure 4. 
LC-MS analysis of compounds produced from assays containing purified enzymes. (i) 
Control reaction without PhnA; (ii) Reaction catalyzed by 5 µM PhnA in the presence of 100 
mM potassium phosphate buffer (pH 7.9) and 2 mM malonyl-CoA; (iii) Reaction catalyzed 
by 5 µM PhnA and 20 µM PhnB in the presence of 100 mM potassium phosphate buffer (pH 
7.9), 2 mM malonyl-CoA, 20 µM FAD, and 4 mM NADPH. Reactions in (i)–(iii) were 
extracted after overnight incubation at 25°C; (iv)–(viii) Time course analysis of 5 µM PhnB 
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catalyzed conversion of 5 to 9 (and the oxidation of 9 to 10). In vitro reaction conditions are 
100 mM potassium phosphate buffer (pH 7.9), 20 µM FAD, 4 mM NADPH and 1 mM 5.
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Figure 5. 
Summary of divergent cyclization regioselectivities of NR-PKSs. All NR-PKSs shown 
synthesize the common heptaketide precursor that is cyclized into the various final products 
due to difference in regioselectivity of the PT domains. The PKS responsible for pannorin 
biosynthesis is not known and is indicated as Pan for illustration purposes. PhnA PT domain 
is unique in that it only catalyzes the C4–C9 cyclization, whereas all previously identified 
PT domains that catalyze C4–C9 cyclization also catalyze the consecutive C2–C11 
cyclization, as in CTB1.
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Figure 6. 
Proposed mechanism for PhnB catalyzed conversion of 5 to 9. PhnB catalyzes the C2-
hydroxlation of 5 through deprotonation of the hemiketal C13 hydroxyl group to yield 14. 
Deprotonation of C3-OH leads to rapid cyclization to form 16 which can undergo 
dehydration and aromatization to yield the product 9. Products that are not observed in the 
reaction, as well as substrate variants that do not react with PhnB are indicated.
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Figure 7. 
Phylogenetic analysis of the PhnA PT domain with its homologs and previously categorized 
Groups I–VPT domains.7a Domains were aligned with ClustalW and the tree was 
constructed with the neighbor-joining method. Scale bar, 0.2 substitutions per site. The 
PhnA homolog group is distinct from Group IV PT domains and form a distinct Group VI. 
This group of PT domains only catalyzes the C4–C9 aldol condensation and the final 
products of the NR-PKSs are multicyclic as in 5. The PhnA PT domain is indicated with a 
red line. Susscrofa fatty acid synthase DH domain is used as an outgroup in the phylogenetic 
analysis. A more comprehensive tree is shown in Figure S6.
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